Board MeetingMay 4, 2026, 04:08 PM
Kyntra Bio Q1 2026 Earnings Call Scheduled for May 11
AI Summary
Kyntra Bio, Inc. announced it will release its first quarter 2026 financial results on Monday, May 11, after market close. The company will also host a conference call and webcast on the same day at 5:00 PM Eastern Time to discuss its corporate and financial performance, followed by a live Q&A session. Kyntra Bio is a biopharmaceutical company focused on oncology and rare disease, with key programs including Roxadustat and FG-3246.
Key Highlights
- Kyntra Bio to announce first quarter 2026 financial results on Monday, May 11.
- A conference call and webcast will be held on May 11 at 5:00 PM Eastern Time.
- Management will discuss financial results and provide a business update.
- Roxadustat is approved in Europe, Japan, and China for anemia in CKD patients.
- FG-3246, an antibody-drug conjugate, is in Phase 2 development for metastatic castration-resistant prostate cancer.
Price Impact
More from KYNB